Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Keros Therapeutics, Inc. (KROS)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
51.19+1.10 (+2.20%)
At close: 04:00PM EST
51.19 0.00 (0.00%)
After hours: 04:00PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close50.09
Open49.45
Bid20.34 x 800
Ask81.36 x 1200
Day's Range47.88 - 51.77
52 Week Range24.38 - 68.29
Volume213,177
Avg. Volume229,387
Market Cap1.198B
Beta (5Y Monthly)1.07
PE Ratio (TTM)N/A
EPS (TTM)-2.68
Earnings DateNov 02, 2022 - Nov 07, 2022
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est95.00
  • Zacks

    Wall Street Analysts Think Keros Therapeutics, Inc. (KROS) Could Surge 95%: Read This Before Placing a Bet

    The average of price targets set by Wall Street analysts indicates a potential upside of 94.9% in Keros Therapeutics, Inc. (KROS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

  • GlobeNewswire

    Keros Therapeutics to Present at Upcoming Healthcare Conferences

    LEXINGTON, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- Keros Therapeutics, Inc. (“Keros”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel treatments for patients suffering from hematological, pulmonary and cardiovascular disorders with high unmet medical need, today announced that Keros’ President and Chief Executive Officer Jasbir S. Seehra, Ph.D., will participate in fireside chat presentations at the Piper Sandler 34

  • Zacks

    Keros Therapeutics, Inc. (KROS) Upgraded to Buy: Here's What You Should Know

    Keros Therapeutics, Inc. (KROS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Advertisement
Advertisement